ultomiris
alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektivni imunosupresivi - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - imunosupresivi - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
soliris
alexion europe sas - Экулизумаб - hemoglobinuria, paroxysmal - imunosupresivi - Солирис indiciran za odrasle i djecu, za liječenje:пароксизмальная noćni гемоглобинурия (apg). dokaza klinički učinak očituje se u bolesnika s гемолизом s klinički simptom(ova), ukazuje na visoke aktivnosti bolesti, bez obzira na priče transfuziju (vidi odjeljak 5. Атипичный гемолитико-уремический (agus). Солирис prikazan kod odraslih za liječenje:vatrostalne postati generalizirani миастенией gravis (ГГМ) u bolesnika s anti-ацетилхолиновому рецептору (АЧР) antitijela (vidi odjeljak 5. poremećaj neuromyelitis vidnog spektra (nmosd) kod pacijenata koji su anti-aquaporin-4 (aqp4) antitijela s recidivom tijekom bolesti.
ultomiris 300 mg/3 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 300 mg/3 ml - 1 bočica sa 3 ml koncentrata za otopinu za infuziju sadrži 300 mg ravulizumaba (100 mg/ml)
ultomiris 1100 mg/11 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 1100 mg/11 ml - 1 bočica sa 11 ml koncentrata za otopinu za infuziju sadrži 1100 mg ravulizumaba (100 mg/ml)
ultomiris 300 mg/30 ml koncentrat za otopinu za infuziju
amicus pharma d.o.o. - ravulizumab - koncentrat za otopinu za infuziju - 300 mg/30 ml - 1 bočica sa 30 ml koncentrata za otopinu za infuziju sadrži 300 mg ravulizumaba (10 mg/ml)
bekemv
amgen technology (ireland) uc - Экулизумаб - hemoglobinuria, paroxysmal - imunosupresivi - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). dokaza klinički učinak očituje se u bolesnika s гемолизом s klinički simptom(ova), ukazuje na visoke aktivnosti bolesti, bez obzira na priče transfuziju (vidi odjeljak 5.
epysqli
samsung bioepis nl b.v. - Экулизумаб - hemoglobinuria, paroxysmal - imunosupresivi - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
prexanil combi a 2,5 mg/0,625 mg 2.5 mg/1 tableta+ 0.625 mg/1 tableta filmom obložena tableta
oktal pharma d.o.o. sarajevo - Индапамид, Периндоприл - filmom obložena tableta - 2.5 mg/1 tableta+ 0.625 mg/1 tableta - jedna filmom obložena tableta sadrži: 2,5 mg perindopril arginin (što odgovara 1,6975 mg perindoprila); 0,625 mg indapamid
gardasil 9
merck sharp & dohme b.v. - cjepivo protiv humanog papiloma virusa [tipovi 6, 11, 16, 18, 31, 33, 45, 52, 58] (rekombinantni, adsorbirani) - condylomata acuminata; papillomavirus infections; immunization; uterine cervical dysplasia - cjepivo protiv папилломавируса - Гардасил 9 prikazana je za aktivne imunizacije ljudi u dobi od 9 godina protiv hpv-a sljedeće bolesti:prekanceroznih lezija i raka, koji utječu na vrat maternice, rukom stimulirati vulvu, vaginu i anus, zbog cjepiva protiv hpv-a typesgenital bradavice (acuminata acuminata) uzrokovanih hpv određene vrste. pogledajte odjeljke 4. 4 i 5. 1 za dobivanje važnih informacija o podacima koji podržavaju ove indikacije. korištenje Гардасила 9 moraju biti u skladu sa službenim preporukama.